Adecatumumab
Adecatumumab is a monoclonal antibody that has been investigated for its potential use in the treatment of various types of cancer. It is specifically designed to target the EpCAM (epithelial cell adhesion molecule), which is overexpressed in many epithelial tumors.
Mechanism of Action[edit | edit source]
Adecatumumab binds to the EpCAM antigen on the surface of tumor cells. This binding can lead to the destruction of the tumor cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). By targeting EpCAM, adecatumumab aims to reduce tumor growth and spread.
Clinical Development[edit | edit source]
Adecatumumab has undergone various stages of clinical trials to evaluate its safety and efficacy. These trials have included patients with different types of carcinomas, such as breast cancer, colorectal cancer, and prostate cancer. The results of these trials have provided insights into the potential benefits and limitations of adecatumumab as a therapeutic agent.
Potential Applications[edit | edit source]
The primary focus of adecatumumab research has been on its application in oncology. Due to its ability to target EpCAM, it has been considered for use in treating cancers that exhibit high levels of this antigen. Researchers are also exploring the possibility of combining adecatumumab with other cancer therapies to enhance its effectiveness.
Side Effects[edit | edit source]
As with many monoclonal antibodies, the use of adecatumumab can be associated with side effects. Common side effects observed in clinical trials include infusion reactions, fatigue, and nausea. More serious side effects may also occur, and the safety profile of adecatumumab continues to be studied.
See Also[edit | edit source]
- Monoclonal antibody therapy
- EpCAM
- Cancer immunotherapy
- Antibody-dependent cellular cytotoxicity
- Complement-dependent cytotoxicity
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
